Akeso Reported 2021 Annual Results ...Middle East

PR Newswire - News
Penpulimab Started Commercialization and Cadonilimab Filed for NDA HONG KONG, April 1, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology &...

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Reported 2021 Annual Results )

Also on site :